| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
5,324 | 5,066 | 22,686 | 8,740 | 3,991 | 52 | |
Acquired in‑process research and development | ||||||
12,151 | 8,815 | - | - | 908 | - | |
General and administrative | ||||||
2,701 | 1,605 | 10,438 | 5,956 | 3,177 | 214 | |
Total operating expenses | ||||||
20,176 | 15,486 | 33,124 | 14,696 | 8,076 | 266 | |
Loss from operations | ||||||
-20,176 | -15,486 | -33,124 | -14,696 | -8,076 | -266 | |
Interest (expense) income, net | ||||||
-22 | -40 | -286 | 114 | -762 | -55 | |
Loss on note extinguishment | ||||||
-1,114 | - | - | - | -198 | - | |
Other income (expense), net | ||||||
- | -3 | -5 | -4 | 7 | 1 | |
Loss before income taxes | ||||||
-21,312 | -15,529 | -33,415 | -14,586 | -9,029 | -320 | |
Provision for income taxes | ||||||
0 | - | - | - | - | - | |
Net loss | ||||||
-21,312 | -15,529 | -33,415 | -14,586 | -9,029 | -320 | |
Other comprehensive loss: | ||||||
Total other comprehensive loss | ||||||
10 | 2 | - | - | - | - | |
Comprehensive loss | ||||||
-21,302 | -15,527 | -33,415 | -14,586 | -9,029 | -320 | |
Net loss | ||||||
-21,312 | -15,529 | -33,415 | -14,586 | -9,029 | -320 | |
Adjustment to redemption value on Series A convertible preferred stock | ||||||
- | - | - | 366 | 2,968 | - | |
Premium upon substantial modification of convertible note with certain shareholders | ||||||
- | - | - | - | 1,047 | - | |
Net loss attributable to common stockholders | ||||||
- | - | -33,415 | -14,952 | -13,044 | -320 | |
Loss per share: | ||||||
Net loss per share, basic and diluted (Note 11) | ||||||
-4.08 | -3.65 | -3.23 | -2.57 | -4.54 | -0.21 | |
Weighted average common shares outstanding: | ||||||
Basic and diluted | ||||||
5,224 | 4,251 | 10,349 | 5,809 | 2,875 | 1,521 | |